A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema.
Latest Information Update: 03 Sep 2021
At a glance
- Drugs Conestat alfa (Primary)
- Indications Hereditary angioedema
- Focus Registrational; Therapeutic Use
- Sponsors Pharming Group NV
Most Recent Events
- 06 Sep 2019 New trial record